Retinal Vein Occlusion - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Retinal Vein Occlusion - Pipeline Review, H2 2018’, provides an overview of the Retinal Vein Occlusion pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion

- The report reviews pipeline therapeutics for Retinal Vein Occlusion by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Retinal Vein Occlusion therapeutics and enlists all their major and minor projects

- The report assesses Retinal Vein Occlusion therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Retinal Vein Occlusion

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Retinal Vein Occlusion

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Retinal Vein Occlusion pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

Addmedica SAS

Aerie Pharmaceuticals Inc

Annexin Pharmaceuticals AB

Cell Medica Ltd

Celon Pharma SA

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Clearside BioMedical Inc ...

3SBio Inc

Addmedica SAS

Aerie Pharmaceuticals Inc

Annexin Pharmaceuticals AB

Cell Medica Ltd

Celon Pharma SA

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Clearside BioMedical Inc

EyeGate Pharmaceuticals Inc

Eyevensys SAS

Formycon AG

Gene Signal International SA

Graybug Vision Inc

Lupin Ltd

Mabion SA

Novartis AG

Ocular Therapeutix Inc

Ohr Pharmaceutical Inc

Oxurion NV

Profarma

Regeneron Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 4

Retinal Vein Occlusion - Overview 5

Retinal Vein Occlusion - Therapeutics Development 6

Retinal Vein Occlusion - Therapeutics Assessment ...

Table of Contents

Table of Contents 2

Introduction 4

Retinal Vein Occlusion - Overview 5

Retinal Vein Occlusion - Therapeutics Development 6

Retinal Vein Occlusion - Therapeutics Assessment 11

Retinal Vein Occlusion - Companies Involved in Therapeutics Development 19

Retinal Vein Occlusion - Drug Profiles 29

Retinal Vein Occlusion - Dormant Projects 94

Retinal Vein Occlusion - Discontinued Products 95

Retinal Vein Occlusion - Product Development Milestones 96

Appendix 108

List of Tables

List of Tables

Number of Products under Development for Retinal Vein Occlusion, H2 2018

Number of Products under Development by Companies, H2 2018

Products under ...

List of Tables

Number of Products under Development for Retinal Vein Occlusion, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Retinal Vein Occlusion - Pipeline by 3SBio Inc, H2 2018

Retinal Vein Occlusion - Pipeline by Addmedica SAS, H2 2018

Retinal Vein Occlusion - Pipeline by Aerie Pharmaceuticals Inc, H2 2018

Retinal Vein Occlusion - Pipeline by Annexin Pharmaceuticals AB, H2 2018

Retinal Vein Occlusion - Pipeline by Cell Medica Ltd, H2 2018

Retinal Vein Occlusion - Pipeline by Celon Pharma SA, H2 2018

Retinal Vein Occlusion - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2018

Retinal Vein Occlusion - Pipeline by Clearside BioMedical Inc, H2 2018

Retinal Vein Occlusion - Pipeline by EyeGate Pharmaceuticals Inc, H2 2018

Retinal Vein Occlusion - Pipeline by Eyevensys SAS, H2 2018

Retinal Vein Occlusion - Pipeline by Formycon AG, H2 2018

Retinal Vein Occlusion - Pipeline by Gene Signal International SA, H2 2018

Retinal Vein Occlusion - Pipeline by Graybug Vision Inc, H2 2018

Retinal Vein Occlusion - Pipeline by Lupin Ltd, H2 2018

Retinal Vein Occlusion - Pipeline by Mabion SA, H2 2018

Retinal Vein Occlusion - Pipeline by Novartis AG, H2 2018

Retinal Vein Occlusion - Pipeline by Ocular Therapeutix Inc, H2 2018

Retinal Vein Occlusion - Pipeline by Ohr Pharmaceutical Inc, H2 2018

Retinal Vein Occlusion - Pipeline by Oxurion NV, H2 2018

Retinal Vein Occlusion - Pipeline by Profarma, H2 2018

Retinal Vein Occlusion - Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Retinal Vein Occlusion - Dormant Projects, H2 2018

Retinal Vein Occlusion - Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Retinal Vein Occlusion, H2 2018 9

Number of Products under Development by Companies, H2 2018 10 ...

List of Figures

Number of Products under Development for Retinal Vein Occlusion, H2 2018 9

Number of Products under Development by Companies, H2 2018 10

Number of Products by Top 10 Targets, H2 2018 14

Number of Products by Stage and Top 10 Targets, H2 2018 14

Number of Products by Top 10 Mechanism of Actions, H2 2018 16

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 16

Number of Products by Routes of Administration, H2 2018 18

Number of Products by Stage and Routes of Administration, H2 2018 18

Number of Products by Molecule Types, H2 2018 20

Number of Products by Stage and Molecule Types, H2 2018 20

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports